Data from: Pre- and post- treatment fold change plasma proteomics in metastatic NSCLC patients

<p>Blood plasma samples were collected from advanced-stage NSCLC patients as part of a clinical study (PROPHETIC; NCT04056247). All clinical sites received IRB approval for the study protocol. Patient blood samples were drawn at baseline (referred to as T0) and, on average, 4 weeks after the treatment commenced, prior to the second dose of treatment (referred to as T1). Blood samples were drawn into tubes containing EDTA as an anticoagulant, and plasma was separated from the whole blood. The protocol adheres to the Clinical and Laboratory Standards Institute (CLSI) guidelines.</p>